{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:38:14Z","timestamp":1787870294530,"version":"build-2784847793"},"reference-count":46,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R61AI49665"],"award-info":[{"award-number":["R61AI49665"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI48055"],"award-info":[{"award-number":["U01AI48055"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI120176"],"award-info":[{"award-number":["UM1AI120176"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.xphs.2021.10.009","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T21:02:00Z","timestamp":1634677320000},"page":"825-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-7823","authenticated-orcid":false,"given":"Simone","family":"Perazzolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4519-303X","authenticated-orcid":false,"given":"Danny D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.xphs.2021.10.009_bib0001","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1016\/S2352-3018(21)00053-9","article-title":"Highlights of virtual CROI 2021","volume":"8","author":"Hayward","year":"2021","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.009_bib0002","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1473-3099(21)00214-0","article-title":"CROI 2021","volume":"21","author":"Kazi","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.xphs.2021.10.009_bib0003","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"25","author":"Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2020.0164","article-title":"A qualitative exploration of women's interest in long-acting injectable antiretroviral therapy across six cities in the women's interagency HIV study: intersections with current and past injectable medication and substance use","volume":"35","author":"Philbin","year":"2021","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/COH.0000000000000591","article-title":"Long-acting implants to treat and prevent HIV infection","volume":"15","author":"Weld","year":"2020","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.xphs.2021.10.009_bib0007","first-page":"3153","article-title":"Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates","volume":"107","author":"Perazzolo","year":"2018","journal-title":"JPharmSci"},{"issue":"17","key":"10.1016\/j.xphs.2021.10.009_bib0008","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1097\/QAD.0000000000001969","article-title":"Extended cell and plasma drug levels after one dose of a 3-in-1 nanosuspension containing lopinavir, efavirenz, and tenofovir in non-human primates","volume":"32","author":"Koehn","year":"2018","journal-title":"AIDS"},{"issue":"7","key":"10.1016\/j.xphs.2021.10.009_bib0009","first-page":"1787","article-title":"Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection","volume":"107","author":"McConnachie","year":"2018","journal-title":"JPharmSci"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.009_bib0010","first-page":"1789","article-title":"Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101","volume":"109","author":"Perazzolo","year":"2020","journal-title":"JPharmSci"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"10.1016\/j.xphs.2021.10.009_bib0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11095-020-02888-8","article-title":"Novel long-acting drug combination nanoparticles composed of gemcitabine and paclitaxel enhance localization of both drugs in metastatic breast cancer nodules","volume":"37","author":"Yu","year":"2020","journal-title":"Pharm Res"},{"key":"10.1016\/j.xphs.2021.10.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2020.08.003","article-title":"Controlled solvent removal from antiviral drugs and excipients in solution enables the formation of novel combination multi-drug-motifs in pharmaceutical powders composed of lopinavir, ritonavir and tenofovir","author":"Yu","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.10.009_bib0014","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J Control Rel"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.009_bib0016","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1128\/AAC.02748-13","article-title":"Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma","volume":"58","author":"Koehn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2021.10.009_bib0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J Angiog Res"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.009_bib0018","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1748-1716.1987.tb08257.x","article-title":"Fluid and protein fluxes across small and large pores in the microvasculature. Application of two-pore equations","volume":"131","author":"Rippe","year":"1987","journal-title":"Acta Physiol Scand"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1208\/s12248-015-9819-4","article-title":"A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins","volume":"18","author":"Gill","year":"2016","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.xphs.2021.10.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013082","article-title":"Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging","volume":"5","author":"Bui","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.009_bib0021","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1152\/japplphysiol.00389.2006","article-title":"A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles","volume":"101","author":"Reddy","year":"2006","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.xphs.2021.10.009_bib0022","series-title":"Encyclopedia of Immunology (Second Edition)","first-page":"1093","article-title":"High endothelial venules","author":"Ager","year":"1998"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.009_bib0023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/smim.1999.0163","article-title":"The physiology of lymphocyte migration through the single lymph node in vivo","volume":"11","author":"Young","year":"1999","journal-title":"Semin Immunol"},{"key":"10.1016\/j.xphs.2021.10.009_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00613","article-title":"T Cell trafficking through lymphatic vessels","volume":"7","author":"Hunter","year":"2016","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.xphs.2021.10.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003586","article-title":"Mathematical modeling reveals kinetics of lymphocyte recirculation in the whole organism","volume":"10","author":"Ganusov","year":"2014","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0026","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/jps.23106","article-title":"Dermal clearance model for epidermal bioavailability calculations","volume":"101","author":"Ibrahim","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.009_bib0027","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1172\/JCI104248","article-title":"Lymphatic flow in human subjects as indicated by the disappearance of I131-labeled albumin from the subcutaneous tissue*","volume":"40","author":"Hollander","year":"1961","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0028","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.1970.tb06100.x","article-title":"Lymphatic function: the disappearance rate of 13Li albumin from the dermis","volume":"82","author":"Ellis","year":"1970","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.009_bib0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0022-4804(83)90131-2","article-title":"Lymphatic flow in humans as indicated by the clearance of 125I-labeled albumin from the subcutaneous tissue of the leg","volume":"35","author":"Fernandez","year":"1983","journal-title":"J Surg Res"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0190-9622(83)70198-2","article-title":"Lymphatic albumin clearance from psoriatic skin","volume":"9","author":"Staberg","year":"1983","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.xphs.2021.10.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000486","article-title":"High-resolution 3D imaging and topological mapping of the lymph node conduit system","volume":"17","author":"Kelch","year":"2019","journal-title":"PLoS Biol"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.009_bib0032","first-page":"117","article-title":"The reticuloendothelial system. An overview of function, pathology and recent methods of measurement","volume":"32","author":"Baas","year":"1994","journal-title":"Z Gastroenterol"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.009_bib0033","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.xphs.2020.11.019","article-title":"Systems and clinical pharmacology of COVID-19 therapeutic candidates: a clinical and translational medicine perspective","volume":"110","author":"Perazzolo","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2021.10.009_bib0034","first-page":"11","article-title":"Bictegravir plus tenofovir alafenamide nanoformulation as a long-acting pre-exposure prophylaxis regimen: application of modeling to design non-human primate pharmacokinetic experiments","author":"Perazzolo","year":"2020","journal-title":"Front Pharmacol"},{"issue":"5-6","key":"10.1016\/j.xphs.2021.10.009_bib0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/1061186X.2018.1433681","article-title":"Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities","volume":"26","author":"Kraft","year":"2018","journal-title":"J Drug Target"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0036","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.it.2012.02.007","article-title":"Lymph node homing of T cells and dendritic cells via afferent lymphatics","volume":"33","author":"F\u00f6rster","year":"2012","journal-title":"Trends Immunol"},{"issue":"12","key":"10.1016\/j.xphs.2021.10.009_bib0037","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/eji.1830051208","article-title":"The migration of recirculating autologous and allogeneic lymphocytes through single lymph nodes","volume":"5","author":"Frost","year":"1975","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.xphs.2021.10.009_bib0038","first-page":"415","article-title":"T-cell recirculation in the sheep: migratory properties of cells from lymph nodes","volume":"47","author":"Reynolds","year":"1982","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0039","first-page":"83","article-title":"The recirculating lymphocyte pool of the rat: a systematic description of the migratory behaviour of recirculating lymphocytes","volume":"49","author":"Smith","year":"1983","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.009_bib0040","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.LAB.0000062852.80567.90","article-title":"Analyzing the migration of labeled T cells in vivo\u00a0: an essential approach with challenging features","volume":"83","author":"Westermann","year":"2003","journal-title":"Lab Invest"},{"issue":"2","key":"10.1016\/j.xphs.2021.10.009_bib0041","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2008-12-192203","article-title":"Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates","volume":"114","author":"Di Mascio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.xphs.2021.10.009_bib0042","series-title":"Current Topics in Microbiology and Immunology","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-642-71272-2_3","article-title":"The regulation of lymphocyte traffic","author":"Butcher","year":"1986"},{"key":"10.1016\/j.xphs.2021.10.009_bib0043","series-title":"Drug Approval Package: VIREAD (Tenofovir Disoproxil Fumarate) Tablets","year":"2001"},{"issue":"4","key":"10.1016\/j.xphs.2021.10.009_bib0044","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095632020901900404","article-title":"Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside\/nucleotide analogues","volume":"19","author":"Zhu","year":"2009","journal-title":"Antivir Chem Chemother"},{"issue":"6","key":"10.1016\/j.xphs.2021.10.009_bib0045","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/S2352-3018(19)30342-X","article-title":"Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV","volume":"7","author":"Bollinger","year":"2020","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.xphs.2021.10.009_bib0046","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jtbi.2008.11.007","article-title":"Scaling aspects of lymphocyte trafficking","volume":"257","author":"Perelson","year":"2009","journal-title":"J Theor Biol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921005529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:37:45Z","timestamp":1758361065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921005529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0022354921005529"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.009","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically Based Pharmacokinetic Modeling of 3 HIV Drugs in Combination and the Role of Lymphatic System after Subcutaneous Dosing. Part 2: Model for the Drug-combination Nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}